NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Stock Short Interest Report for October

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 5,262 shares, a growth of 473.2% from the October 15th total of 918 shares. Based on an average daily volume of 2,157 shares, the days-to-cover ratio is currently 2.4 days.

NeuroSense Therapeutics Trading Up 35.7%

Shares of NASDAQ NRSNW traded up $0.00 during mid-day trading on Wednesday, hitting $0.01. 23,085 shares of the stock traded hands, compared to its average volume of 3,754. The stock has a fifty day moving average price of $0.03 and a 200-day moving average price of $0.13. NeuroSense Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.47.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on biological processes associated with nerve-cell damage and disease progression. The company’s lead investigational product, PrimeC, is an oral formulation combining ciprofloxacin and celecoxib. NeuroSense is developing PrimeC primarily for amyotrophic lateral sclerosis (ALS); it is investigational and has not been approved as a treatment.